[go: up one dir, main page]

AU9551201A - Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates - Google Patents

Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates

Info

Publication number
AU9551201A
AU9551201A AU9551201A AU9551201A AU9551201A AU 9551201 A AU9551201 A AU 9551201A AU 9551201 A AU9551201 A AU 9551201A AU 9551201 A AU9551201 A AU 9551201A AU 9551201 A AU9551201 A AU 9551201A
Authority
AU
Australia
Prior art keywords
oral
treatment
dopaminergic
therapeutic system
transdermal therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU9551201A
Inventor
Reinhard Horowski
Johannes Tack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU9551201A publication Critical patent/AU9551201A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.
AU9551201A 2000-10-20 2001-08-24 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates Pending AU9551201A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10053397A DE10053397A1 (en) 2000-10-20 2000-10-20 Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases
PCT/EP2001/009826 WO2002034267A1 (en) 2000-10-20 2001-08-24 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states

Publications (1)

Publication Number Publication Date
AU9551201A true AU9551201A (en) 2002-05-06

Family

ID=7661331

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001295512A Ceased AU2001295512B2 (en) 2000-10-20 2001-08-24 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states
AU9551201A Pending AU9551201A (en) 2000-10-20 2001-08-24 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001295512A Ceased AU2001295512B2 (en) 2000-10-20 2001-08-24 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states

Country Status (9)

Country Link
US (2) US7258871B2 (en)
EP (1) EP1303278B1 (en)
JP (1) JP2004512305A (en)
AT (1) ATE413177T1 (en)
AU (2) AU2001295512B2 (en)
DE (2) DE10053397A1 (en)
DK (1) DK1303278T3 (en)
ES (1) ES2315309T3 (en)
WO (1) WO2002034267A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
DE10053397A1 (en) 2000-10-20 2002-05-02 Schering Ag Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases
DE10066158B4 (en) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Use of a transdermal therapeutic system for the treatment of Restless Legs Syndrome
DE10064453A1 (en) * 2000-12-16 2002-07-04 Schering Ag Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE10226459A1 (en) * 2002-06-13 2004-01-08 Neurobiotec Gmbh Use of dopamine partial agonists to treat restless legs syndrome
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
WO2008001200A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal composition having enhanced color stability
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
AU2015201255B2 (en) * 2008-01-14 2016-05-19 Veroscience, Llc Parenteral formulations of dopamine agonists
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
WO2011116220A2 (en) * 2010-03-17 2011-09-22 Arbonne International Llc Oral supplement
CA2815959C (en) * 2010-11-01 2020-10-06 Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms
CN113149982A (en) 2015-01-20 2021-07-23 Xoc制药股份有限公司 Ergoline compounds and uses thereof
CN108785286A (en) * 2017-04-28 2018-11-13 日东电工株式会社 Transdermal absorption formulation
EP3630758A1 (en) 2017-06-01 2020-04-08 Xoc Pharmaceuticals, Inc Ergoline derivatives for use in medicine

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US559782A (en) * 1896-05-05 Aaron mosley
CH573936A5 (en) * 1971-08-05 1976-03-31 Spofa Vereinigte Pharma Werke
DE2359128A1 (en) * 1973-11-24 1975-06-12 Schering Ag MEDICINAL PRODUCTS BASED ON LISURIDE AND ITS PHYSIOLOGICALLY COMPATIBLE SALT
US3985752A (en) 1974-12-06 1976-10-12 Eli Lilly And Company 6-Methyl-8-(substituted) methylergolines
US4166182A (en) * 1978-02-08 1979-08-28 Eli Lilly And Company 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds
US4202979A (en) 1979-01-11 1980-05-13 Eli Lilly And Company 6-Ethyl(or allyl)-8-methoxymethyl or methylmercaptomethylergolines and related compounds
DE3063869D1 (en) * 1979-06-13 1983-07-28 Schering Ag (ergolin-yl)-n', n'-diethyl urea derivatives, their preparation and pharmaceutical compositions containing them
HU180467B (en) * 1979-07-12 1983-03-28 Gyogyszerkutato Intezet Process for producing new ergol-8-ene- and ergoline-sceleted compounds
DE3101535A1 (en) 1981-01-14 1982-08-12 Schering Ag, 1000 Berlin Und 4619 Bergkamen NEW (2-HALOGEN-ERGOLINYL) -N'.N'-DIETHYL-UREA DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT
US4742054A (en) * 1982-11-23 1988-05-03 Naftchi Nosrat E Treatment of mammals suffering from damage to the central nervous system
DE3333240A1 (en) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen MEDIUM FOR TRANSDERMAL APPLICATION OF MEDICINAL PRODUCTS
KR920010392B1 (en) 1984-03-01 1992-11-27 산도즈 아크리엔 게젤샤프트 Process for preparing pharmaceutical composition for the transdermal systemic administration
US5364628A (en) * 1985-05-31 1994-11-15 Sandoz Ltd. Pharmaceutical compositions
DE3445784A1 (en) * 1984-12-13 1986-06-26 Schering AG, Berlin und Bergkamen, 1000 Berlin METHOD FOR PRODUCING ERGOLIN DERIVATIVES
IT1200603B (en) * 1985-04-04 1989-01-27 Poli Ind Chimica Spa PHARMACEUTICAL COMPOSITION WITH DOPAMINERGIC ACTIVITY
US4935429A (en) * 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
US4800204A (en) * 1987-05-07 1989-01-24 Mueller Peter S Method of controlling tobacco use
US4798834A (en) * 1987-08-31 1989-01-17 Eli Lilly And Company Optionally substituted (3β-9,10-didehydro-2,3-dihydro ergoline as serotonergic function enhancement
US4797405A (en) 1987-10-26 1989-01-10 Eli Lilly And Company Stabilized pergolide compositions
IT1223343B (en) 1987-11-03 1990-09-19 Also Lab Sas PHARMACEUTICAL FORMULATIONS FOR TRANSDERMAL ADMINISTRATION
CA1336169C (en) * 1988-03-01 1995-07-04 Walther Birkmayer Agent for treatment of parkinson's disease
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5378730A (en) * 1988-06-09 1995-01-03 Alza Corporation Permeation enhancer comprising ethanol and monoglycerides
US5252335A (en) * 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5229129A (en) * 1989-07-12 1993-07-20 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5114948A (en) * 1989-10-19 1992-05-19 Eli Lilly And Company Stabilized pergolide compositions
DE3937271A1 (en) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg TRANSDERMAL APPLICATION OF 2-AMINO-6-N-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE
US5462744A (en) * 1989-12-01 1995-10-31 Boehringer Ingelheim Kg Transdermal system for the administration of pharmacological compounds under pH-controlled conditions
ZA912984B (en) 1990-04-25 1992-01-29 Alza Corp Treatment of erectile dysfunction
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5190763A (en) 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5192550A (en) 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5063234A (en) 1990-05-25 1991-11-05 Eli Lilly And Company Method of inhibiting demineralization of bone
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
PT99864B (en) 1990-12-21 1999-06-30 Schering Ag METHOD FOR PREPARING NEW PHARMACEUTICAL COMPOSITIONS CONTAINING QUISQUALATE RECEPTOR ANTAGONISTS
CA2080119A1 (en) * 1991-02-08 1992-08-09 Heidi Hummel-Maquardt Process for the production of ergoline derivatives
JPH06507392A (en) 1991-02-26 1994-08-25 エイアールシー　１，インコーポレイテッド Compositions and methods for the treatment of sympathetic persistent pain
DE4116912A1 (en) * 1991-05-18 1992-11-26 Schering Ag ERGOLIN DERIVATIVES CONTAINING MEANS OF TRANSDERMAL APPLICATION
IT1252163B (en) 1991-12-03 1995-06-05 Poli Ind Chimica Spa PHARMACEUTICAL COMPOSITIONS FOR NEUROPROTECTION IN DEGENERATIVE OR ISCHEMIC-BASED NEUROLOGICAL DISEASES
SE513429C2 (en) 1992-06-03 2000-09-11 Syntello Inc Preparations for activating natural killer cells, which contain interferon alfa and biogenic amines
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
PT690863E (en) * 1993-04-06 2003-07-31 Abbott Lab TETRACICLIC COMPOUNDS AS DOPAMINE AGONISTS
CA2161004C (en) * 1993-04-20 2004-10-26 Wilfried Fischer Active ingredient patch
DE4313402A1 (en) 1993-04-23 1994-10-27 Hexal Pharma Gmbh Transdermal preparation of active compound
US5674875A (en) 1993-05-04 1997-10-07 Eli Lilly And Company Method of blocking human 5-hydroxytryptamine-2 receptors
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
DE4440337A1 (en) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmaceutical nanosuspensions for drug application as systems with increased saturation solubility and dissolution rate
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US5696125A (en) 1995-02-24 1997-12-09 Research Foundation Of The State University Of New York Substance abuse-induced hemorrhagic stoke in an animal model
AU5317996A (en) 1995-04-18 1996-11-07 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor
US5643586A (en) * 1995-04-27 1997-07-01 Perricone; Nicholas V. Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds
GB9511366D0 (en) 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
US6572879B1 (en) 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US5807570A (en) 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5877183A (en) * 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
DE19626621A1 (en) 1996-07-02 1998-01-08 Hexal Ag Plaster for transdermal application of pergolide
US6623752B1 (en) * 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
WO1998009523A1 (en) 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6391871B1 (en) 1996-09-20 2002-05-21 John W. Olney Preventing neuronal degeneration in Alzheimer's disease
DE19644998C1 (en) 1996-10-30 1998-06-10 Hanns Prof Dr Ludwig Use of adamantane amines or structurally analogous compounds for combating Borna Disease Virus and for the prophylaxis and treatment of affect diseases and other disorders associated with BDV infections in humans and animals
US6001861A (en) 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
US5849800A (en) * 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
GB9711043D0 (en) 1997-05-29 1997-07-23 Ciba Geigy Ag Organic compounds
KR100597517B1 (en) 1998-03-27 2006-07-10 파마시아 앤드 업존 캄파니 엘엘씨 Use of cabergoline to treat restless leg syndrome
DE19814083C2 (en) 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Process for the production of transdermal therapeutic systems using basic alkali metal salts for converting active substance salts into the free bases
DE19814087A1 (en) 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Moisture-activated therapeutic system
KR20010043612A (en) 1998-05-15 2001-05-25 로렌스 티. 마이젠헬더 Cabergoline and Pramipexole: New Uses and Combinations
DE19821788C1 (en) 1998-05-15 1999-12-02 Sanol Arznei Schwarz Gmbh Transdermal therapeutic system (TTS) containing pergolide
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
FR2786101B1 (en) 1998-11-24 2002-07-05 Aventis Laboratoire USE OF NICERGOLIN IN THE TREATMENT OF SPASTICITY
IT1307934B1 (en) 1999-01-27 2001-11-29 Poli Ind Chimica Spa PROCESS FOR THE PREPARATION OF ALCHEMERCAPTOMETHYLERGOLINIC DERIVATIVES.
WO2000057851A2 (en) 1999-03-26 2000-10-05 Pozen Inc. High potency dihydroergotamine compositions
FR2792529B1 (en) 1999-04-26 2001-09-28 Sod Conseils Rech Applic NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING 2-ISOXAZOLE-8-AMINOTETRALINE DERIVATIVES
ES2206240T3 (en) 1999-06-09 2004-05-16 Chiesi Farmaceutici S.P.A. AMINOTETRALINE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS.
DE19938823A1 (en) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Treatment of restless leg syndrome symptoms, using synergistic combination of alpha-2 agonist, preferably clonidine, and another neuro-psychic drug, e.g. pramipexol
EP1218003A4 (en) 1999-09-13 2004-02-11 David M Swope Composition and method for decreasing neurologic symptomatology
US20020193740A1 (en) 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
DE10054713C2 (en) 1999-11-29 2002-07-18 Lohmann Therapie Syst Lts Transdermal therapeutic systems with improved stability and a method for their production
ATE245972T1 (en) * 1999-11-29 2003-08-15 Lohmann Therapie Syst Lts TRANSDERMAL THERAPEUTIC SYSTEMS WITH IMPROVED STABILITY AND A METHOD FOR THE PRODUCTION THEREOF
US20020009486A1 (en) 1999-11-30 2002-01-24 3M Innovative Properties Company Therapeutic agent delivery incorporating reflective optical film
US20020110585A1 (en) 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
US6613507B1 (en) 2000-03-21 2003-09-02 Yu-an Chang Boraadamantane compounds for the treatment of pathogenic viruses and other medical applications
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007193D0 (en) 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
IL152751A0 (en) 2000-05-12 2003-06-24 Chiesi Farma Spa Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
US20020019421A1 (en) 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
DE10341317B4 (en) 2003-09-03 2008-10-23 Axxonis Pharma Ag Transdermal therapeutic system (TTS) for administration of ergoline compounds except pergolide
DE10066158B4 (en) 2000-08-24 2007-08-09 Neurobiotec Gmbh Use of a transdermal therapeutic system for the treatment of Restless Legs Syndrome
DE10053397A1 (en) 2000-10-20 2002-05-02 Schering Ag Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases
DE10041479A1 (en) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh New pharmaceutical composition for the administration of N-0923
US6388079B1 (en) 2000-08-29 2002-05-14 Scinopharm Singapore Pte Ltd. Process for preparing pergolide
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
AR031152A1 (en) 2000-10-31 2003-09-10 Upjohn Co NEW TREATMENTS FOR THE CONCERNED LEG SYNDROME
DE10064453A1 (en) 2000-12-16 2002-07-04 Schering Ag Use of a dopaminergic active ingredient for the treatment of dopaminerg treatable diseases
US20020123503A1 (en) 2000-12-21 2002-09-05 Malcolm Ross Cabergoline pharmaceutical compositions and methods of use thereof
JP2005504717A (en) 2001-01-16 2005-02-17 パーデュー・リサーチ・ファウンデーション Treatment of dopamine-related dysfunction
US20040170672A1 (en) 2001-03-07 2004-09-02 Thorsten Selzer Transdermal therapeutic system for administration of partial dopamine-d2 agonists
DE10110953A1 (en) 2001-03-07 2002-09-19 Lohmann Therapie Syst Lts Transdermal therapeutic system for the administration of partial dopamine D2 agonists
US7988991B2 (en) 2001-03-07 2011-08-02 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
WO2002078602A2 (en) 2001-03-30 2002-10-10 Elan Pharmaceuticals, Inc. Transdermal delivery of pergolide
US6632217B2 (en) 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
US6770638B2 (en) 2001-04-20 2004-08-03 Spectrum Pharmaceuticals, Inc. Tetrahydroindolone and purine derivatives linked to arylpiperazines
ATE437637T1 (en) 2001-05-02 2009-08-15 Nitromed Inc NITROZED AND NITROSYLATED NEBIVOLOL AND ITS METABOLITES, COMPOSITIONS AND METHODS OF USE
US20030026830A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
EP1256343B1 (en) 2001-05-11 2006-07-05 Jürgen K. Dr. Beck Flibanserin for the treatment of extrapyramidal movement disorders
US6500857B1 (en) 2001-08-16 2002-12-31 Nicholas V. Perricone Subcutaneous muscle treatment using electronic stimulation and topical compositions
US20020193758A1 (en) 2001-06-18 2002-12-19 Sca Hygiene Products Ab Product
SE0102152L (en) 2001-06-18 2002-12-19 Sca Hygiene Prod Ab New product
US20030073609A1 (en) 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
DE10137082A1 (en) 2001-07-28 2003-02-13 Hexal Ag Stable transdermal therapeutic system containing pramipexol or ropinirol, especially for treating Parkinson's disease, comprises backing, drug-containing pressure-sensitive adhesive matrix and protective layers
DE10137162A1 (en) 2001-07-30 2003-02-20 Hexal Ag Transdermal therapeutic system for administration of pramipexole or ropinirole for treating Parkinson's disease, comprises backing layer, reservoir, semipermeable membrane, adhesive layer and protecting layer
EP1421955A1 (en) 2001-08-10 2004-05-26 Hisamitsu Pharmaceutical Co., Inc. Percutaneous absorption preparations
US20030181462A1 (en) 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
FR2829028B1 (en) 2001-08-29 2004-12-17 Aventis Pharma Sa COMBINATION OF AN ANTAGONIST OF THE CB1 RECEPTOR AND A PRODUCT THAT ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF DISEASE
US20040120995A1 (en) 2002-04-01 2004-06-24 Martin Debra A Transdermal delivery of pergolide
US20040105889A1 (en) 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US20040048779A1 (en) 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US20040166159A1 (en) 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US7160913B2 (en) 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
DK1551370T3 (en) 2002-10-11 2008-03-03 Idea Ag Aggregate with enhanced deformability, comprising at least three amphiphates, for enhanced transport through semipermeable barriers and for non-invasive drug delivery in vivo, especially through the skin
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
NZ540493A (en) 2002-12-19 2008-04-30 Schering Corp Uses of adenosine A2a receptor antagonists
CN1816524B (en) 2003-01-16 2012-06-27 阿卡蒂亚药品公司 Selective serotonin 2A/2C receptor inverse agonists for the treatment of neurodegenerative diseases
DE10305137A1 (en) 2003-02-07 2004-08-26 Novosis Ag Transdermal therapeutic delivery systems with a butenolide
ES2487415T3 (en) 2003-03-17 2014-08-20 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological deficiencies associated with brain lesions
SI1610791T1 (en) 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
IL155545A (en) 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline

Also Published As

Publication number Publication date
US20040092544A1 (en) 2004-05-13
DK1303278T3 (en) 2009-02-09
JP2004512305A (en) 2004-04-22
DE10053397A1 (en) 2002-05-02
US20050214353A1 (en) 2005-09-29
WO2002034267A1 (en) 2002-05-02
AU2001295512B2 (en) 2006-09-21
ATE413177T1 (en) 2008-11-15
EP1303278A1 (en) 2003-04-23
ES2315309T3 (en) 2009-04-01
WO2002034267A8 (en) 2002-05-23
US7258871B2 (en) 2007-08-21
EP1303278B1 (en) 2008-11-05
DE50114474D1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
AU9551201A (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates
NO993520D0 (en) Dosage forms and methods for improving erectile dysfunction
MXPA06001815A (en) Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease.
HUP0204163A2 (en) Controlled-release composition containing opioid agonist and antagonist and process for its preparation
BG66093B1 (en) Controlled release compositions comprising nimesulide
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
BR0314356A (en) Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods using the same
AU1046302A (en) Transdermal therapeutic system
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
YU2603A (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation
YU49026B (en) THE USE OF 17 ß -(N-TERT-BUTYLCARBAMOYIL)-4-AZA-5-ALPHA-ANDROST-1-ENE-3-ONE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ANDROGENIC ALOPECIA
IL128723A0 (en) Pharmaceutical compositions containing rar antagonists and rxr agonists
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
BR0311903A (en) Treatment for depression and anxiety by combining an iv pde inhibitor and an antidepressant or anxiolytic agent
IL140716A0 (en) Use of inhibitors of protein kinase c epsilon to treat pain
MXPA02003484A (en) Synergistic combinations of an nk1.
CA2454699A1 (en) Method for treating primary insomnia
GB9930075D0 (en) Medicaments
BR0005319A (en) Combined treatment for depression and anxiety
EP1051995A3 (en) 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU8900498A (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
UA26886C2 (en) 1,3-diaryl-4,5-polymethylenimidazole salts, demonstrating analgesic activity